BioAtla, Inc. (BCAB)

Market Cap	188.59M
Revenue (ttm)	n/a
Net Income (ttm)	-102.33M
Shares Out	46.11M
EPS (ttm)	-2.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	332,033
Open	4.15
Previous Close	4.14
Day's Range	4.02 - 4.31
52-Week Range	2.01 - 12.15
Beta	0.63
Analysts	Buy
Price Target	26.67 (+552.08%)
Earnings Date	Mar 7, 2023

About BCAB

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 16, 2020
• Employees: 56
• Stock Exchange: NASDAQ
• Ticker Symbol: BCAB

Financial Performance

In 2021, BioAtla's revenue was $250,000, a decrease of -41.72% compared to the previous year's $429,000. Losses were -$95.40 million, 166.1% more than in 2020.

Analyst Forecast

According to 13 analysts, the average rating for BCAB stock is "Buy." The 12-month stock price forecast is $26.67, which is an increase of 552.08% from the latest price.

Price Target

$26.67

(552.08% upside)

Analyst Consensus: Buy